Trastuzumab and regorafenib for advanced liver cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hepatocellular carcinoma (liver cancer).
- You must have received a prior immunotherapy combined with a targeted drug (such as atezolizumab + bevacizumab or similar), and your cancer has gotten worse despite that treatment.
- Your liver function must be relatively good (Child-Pugh score ≤ 7).
- You must be able to perform daily activities with little to no help (ECOG score 0-1).
- Your blood counts and kidney/liver function must be within acceptable limits as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer whose disease progressed after or couldn't tolerate first-line immunotherapy. The goal is to see if this drug can slow or shrink the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.